Sunday, January 9, 2022

Biden administration guidance prioritizes race in administering COVID drugs

One such "risk factor" is being a race or ethnicity that is not White due to "longstanding systemic health and social inequities."

"Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19," the memo reads.

In guidelines issued by the state of Utah for the distribution of monoclonal antibodies in the state, residents who are "non-white race or Hispanic/Latinx ethnicity" receive 2 additional points when calculating their "COVID-19 risk score."

"Race/ethnicity continues to be a risk factor for severe COVID-19 disease, and the Utah COVID Risk Score is one approach to address equitable access to hard hit communities," the Utah guidance stated, adding a reminder that national guidance from the FDA "specifically states that race and ethnicity may be considered when identifying patients most likely to benefit from this lifesaving treatment."

A healthcare worker attaches an IV infusion to a patient's hand during a monoclonal antibody treatment in the parking lot at Wayne Health Detroit Mack Health Center in Detroit, Michigan, U.S., on Thursday, Dec. 23, 2021. 

Similarly, the framework issued by the state of Minnesota advises clinicians and health systems to "consider heightened risk of progression to severe COVID-19 associated with race and ethnicity when determining eligibility" for the allocation for monoclonal antibody therapies.

"FDA's acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for mAbs," the framework states. "It is ethically appropriate to consider race and ethnicity in mAb eligibility decisions when data show elevated risk of poor COVID-19 outcomes for Black, Indigenous and other people of color (BIPOC populations), and that this risk cannot be adequately addressed by determining eligibility based on underlying health conditions (perhaps due to underdiagnosis of health conditions that elevate risk of poor COVID-19 outcomes in these populations)."



No comments:

Post a Comment